AVEO third quarter total collaboration revenues boost to $6.2 million AVEO Pharmaceuticals, Inc. , a biopharmaceutical organization focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, along with recent developments. Through the third quarter, we accomplished two significant developments – completing enrollment of TIVO-1, our Phase 3 scientific trial of tivozanib in patients with advanced kidney cancers, which advances the anticipated timeline for top-collection data for TIVO-1 by half a year to mid-2011, and regaining worldwide rights to AV-299, our internally-discovered anti-HGF antibody, stated Tuan Ha-Ngoc, president and chief executive officer of AVEO.Again, there have been several mistakes with the formulation of early mouthwash products a few of which caused cancer. It is the benzene component which makes this bad for people. Sometimes, bacteria could be good. Sometimes, it really is detrimental to be obsessed with oral hygiene. Without bacteria, we are in trouble. Without these, we shall have trouble functioning properly. What is being discussed this is actually the mouth.